OHDSI MEETINGS THIS WEEK
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.9868221
Maternal & Child Health WG meeting - Tuesday at 2pm CEThttps://global.gotomeeting.com/join/637158965
Population-Level Estimation (Western hemisphere) workgroup meeting - Thursday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL&rnd=454318.20161
Hadoop WG meeting - Friday at 11am EThttp://cloudera.webex.com/meet/sdolley
GIS working group meeting - Monday (December 11th) at 10am EThttps://tufts.webex.com/mw3200/mywebex/default.do?service=1&siteurl=tufts&nomenu=true&main_url=%2Fmc3200%2Fe.do%3Fsiteurl%3Dtufts%26AT%3DMI%26EventID%3D562301137%26UID%3D528546812%26Host%3DQUhTSwAAAAT_EHuT3Ok-zHVhY1-kVGh78TH62dPsFk0x99qz1E9039sh_Eiepw8CoZeIF2SfnopQ8oAZaLN9PkzIZovRf2kV0%26FrameSet%3D2%26MTID%3Dm243d8e9a9c6c2d42d5182aeb5d30efdb1
ANNOUNCEMENTS
State of the Collaborative Address - CALL FOR PARTICIPATION
During our opening community call of 2018 (either January 9th or 16th) we'll be giving our annual state of the collaborative address. We want to hear from you guys, what your experience of OHDSI has been in 2017. Whether that was publishing papers,...
2017 OHDSI Symposium Materials - Presentation slides from this year’s symposium and tutorials have been uploaded here: https://www.ohdsi.org/past-events
Symposium Videos - Recordings from the symposium are now available here: https://www.ohdsi.org/past-events/2017-ohdsi-symposium-materials/2017-ohdsi-sympoium-videos/
Tutorial videos: https://www.ohdsi.org/past-events/2017-tutorials-omop-common-data-model-and-standardized-vocabularies/ https://www.ohdsi.org/past-events/2017-tutorials-population-level-estimation/ https://www.ohdsi.org/past-events/2017-tutorials-ohdsi-development-architecture/ https://www.ohdsi.org/past-events/2017-tutorials-patient-level-prediction/
There is nothing so stable as change.
COMMUNITY PUBLICATIONS
Methods for examining data quality in healthcare integrated data repositorieshttp://www.worldscientific.com/doi/abs/10.1142/9789813235533_0059
A survey of practices for the use of electronic health records to support research recruitment
System for Collecting Biosignal Data from Multiple Patient Monitoring Systems.
D Yoon, S Lee, TY Kim, J Ko, WY Chung and RW Park,
Healthcare informatics research , Oct 2017
Biosignal data include important physiological information. For that reason, many devices and systems have been developed, but there has not been enough consideration of how to collect and integrate raw data from multiple systems. To overcome this limitation, we have developed a system for collecting and integrating biosignal data from two patient monitoring systems.We developed an interface to extract biosignal data from Nihon Kohden and Philips monitoring systems. The Nihon Kohden system has a central server for the temporary storage of raw waveform data, which can be requested using the HL7 protocol. However, the Philips system used in our hospital cannot save raw waveform data. Therefore, our system was connected to monitoring devices using the RS232 protocol. After collection, the data were transformed and stored in a unified format.From September 2016 to August 2017, we collected approximately 117 patient-years of waveform data from 1,268 patients in 79 beds of five intensive care units. Because the two systems use the same data storage format, the application software could be run without compatibility issues.Our system collects biosignal data from different systems in a unified format. The data collected by the system can be used to develop algorithms or applications without the need to consider the source of the data.
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study.
SC You, H Park, D Yoon, S Park, B Joung and RW Park,
The Korean journal of internal medicine , Nov 27 2017
Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of enteropathy in Korea.Our retrospective cohort study used data from the Korean National Health Insurance Service to identify 108,559 patients (58,186 females) who were initiated on angiotensin converting enzyme inhibitors (ACEis), olmesartan, or other ARBs between January 2005 and December 2012. The incidences of enteropathy were compared among drug groups. Changes in body weight were compared after propensity score matching of patients in the ACEis and olmesartan groups.Among 108,559 patients, 31 patients were diagnosed with enteropathy. The incidences were 0.73, 0.24, and 0.37 per 1,000 persons, in the ACEis, olmesartan, and other ARBs groups, respectively. Adjusted rate ratios for enteropathy were: olmesartan, 0.33 (95% confidential interval [CI], 0.10 to 1.09; p = 0.070) and other ARBs, 0.34 (95% CI, 0.14 to 0.83; p = 0.017) compared to the ACEis group after adjustment for age, sex, income level, and various comorbidities. The post hoc analysis with matched cohorts revealed that the proportion of patients with significant weight loss did not differ between the ACEis and olmesartan groups.Olmesartan was not associated with intestinal malabsorption or significant body weight loss in the general Korean population. Additional large-scale prospective studies of the relationship between olmesartan and the incidence of enteropathy in the Asian population are needed.
Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses.
J Sultana, M Calabró, R Garcia-Serna, C Ferrajolo, C Crisafulli, J Mestres and G Trifirò',
PloS one , 2017
Antipsychotic (AP) safety has been widely investigated. However, mechanisms underlying AP-associated pneumonia are not well-defined.The aim of this study was to investigate the known mechanisms of AP-associated pneumonia through a systematic literature review, confirm these mechanisms using an independent data source on drug targets and attempt to identify novel AP drug targets potentially linked to pneumonia.A search was conducted in Medline and Web of Science to identify studies exploring the association between pneumonia and antipsychotic use, from which information on hypothesized mechanism of action was extracted. All studies had to be in English and had to concern AP use as an intervention in persons of any age and for any indication, provided that the outcome was pneumonia. Information on the study design, population, exposure, outcome, risk estimate and mechanism of action was tabulated. Public repositories of pharmacology and drug safety data were used to identify the receptor binding profile and AP safety events. Cytoscape was then used to map biological pathways that could link AP targets and off-targets to pneumonia.The literature search yielded 200 articles; 41 were included in the review. Thirty studies reported a hypothesized mechanism of action, most commonly activation/inhibition of cholinergic, histaminergic and dopaminergic receptors. In vitro pharmacology data confirmed receptor affinities identified in the literature review. Two targets, thromboxane A2 receptor (TBXA2R) and platelet activating factor receptor (PTAFR) were found to be novel AP target receptors potentially associated with pneumonia. Biological pathways constructed using Cytoscape identified plausible biological links potentially leading to pneumonia downstream of TBXA2R and PTAFR.Innovative approaches for biological substantiation of drug-adverse event associations may strengthen evidence on drug safety profiles and help to tailor pharmacological therapies to patient risk factors.
